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Abstract
Objective
Patients with inflammatory bowel disease (IBD) demonstrate an inflammatory response
which bears some similarities to that seen in ischaemic heart disease (IHD). The nature of
the association of IBD with IHD is uncertain. We aimed to define the extent and direction of
that association.
Design
This retrospective cohort study examined records from patients aged 15 years with IBD
from 1987–2009 (n = 19163) who were age and gender matched with patients without IBD
(n = 75735) using the General Practice Research Database. The primary outcome was the
hazard ratio for IHD.
Results
A higher proportion of IBD patients had a recorded diagnosis of IHD ever, 2220 (11.6%)
compared with 6504 (8.6%) of controls. However, the majority (4494, 51.5%) developed
IHD prior to IBD diagnosis (1404 (63.2%) of IBD cases and 3090 (47.5%) of controls). There
was increased IHD incidence in the first year after IBD diagnosis. Mean age at IHD diagno-
sis was statistically similar across all IBD groups apart from for those with Ulcerative Colitis
(UC) who were slightly younger at diagnosis of angina compared to controls (64.5y vs.
67.0y, p = 0.008) and coronary heart disease (65.7y vs.67.9y, p = 0.015). Of those develop-
ing IHD following IBD diagnosis, UC patients were at higher risk of IHD (unadjusted HR 1.3
(95% CI 1.1–1.5), p<0.001) or MI (unadjusted HR 1.4 (95% CI 1.1–1.6), p = 0.004).
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Conclusion
Although IHD prevalence was higher in IBD patients, most IHD diagnoses predated the
diagnosis of IBD. This implies a more complex relationship than previously proposed
between the inflammatory responses associated with IHD and IBD, and alternative models
should be considered.
Introduction
The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s Disease (CD) are
disorders of uncertain origin. In both UC and CD, an exaggerated immune response to
unknown antigens is evident [1] and a number of cytokines with pro-inflammatory effects
have been described, notably IFN-ƴ and IL-17/IL-22 in Crohn’s disease, IL-13, TNF-α, IL-1β,
IL-6 and TL1A in ulcerative colitis.[2, 3] The inflammatory response in IBD bears a number of
similarities to that seen in rheumatoid arthritis, where TNF-α, IL-1 and IL-6 are prominent
factors in synovial inflammation.[4] In both diseases, cytokine and acute phase protein levels
are elevated, angiogenesis is up-regulated and endothelial dysfunction can be demonstrated [4,
5, 6] These similarities also exist with other diseases with an underlying inflammatory basis,
such as psoriasis[7] and diabetic nephropathy.[8]
There is a well-described association between rheumatoid arthritis (RA) and increased car-
diovascular mortality, mainly as a result of ischaemic heart disease (IHD).[9, 10] Atherosclero-
sis is increasingly recognized as a chronic inflammatory disorder, with evidence for endothelial
dysfunction, and angiogenesis. More recently a causal relationship between IL-6R related path-
ways and coronary heart disease has been established.[11]
There are sufficient shared characteristics to the inflammatory responses seen in IBD and
RA to hypothesise that the recognized association between RA and IHDmight also exist for
IBD and IHD. Previous cohort studies have examined the risk of IHD in patients with IBD and
have variously found no effect,[12] or a slight increased risk [13]. A large Danish cohort study
[13] found a high risk of IHD diagnosis in the first year after IBD diagnosis, followed by a
small but statistically significant increased risk in subsequent years, a risk which decreased
among users of 5-aminosalicylic acid (5-ASA) preparations. In this study we investigated both
the strength and direction of association between IBD and IHD (including its sub-entities myo-
cardial infarction (MI) and angina) in a large British cohort.
Methods
Study Population
The study population for this retrospective cohort study consisted of around 2.1 million male
and female patients with an active registration at practices contributing to the General Practice
Research Database (GPRD, now accessed via the Clinical Practice Research Datalink, http://
www.cprd.com/home/) between 1987 and 2009. For each subject with IBD, a further 4 subjects
were identified and matched for age and sex but without IBD. All cohort members were fol-
lowed from the start date (i.e. the date their GPRD record began) until the earliest occurrence
of one of the following endpoints: recorded code of IHD, death, date of exit from GPRD regis-
tered GP practice, or end of study period (31.12.2009). Patients with less than (1) 2 years up-
to-standard enrolment with the GP or (2) 1 year of computerized prescription history or (3) no
health contacts during their complete period of follow-up were excluded from the cohort.
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Patients whose date of death or date of transfer out of a GPRD-registered practice preceded
date of IBD diagnosis were excluded from the cohort. Patients<15 years of age at entry were
excluded.
Disease definitions
We identified all male and female patients with a first diagnosis of IBD who met the following
criteria: a first record of ulcerative colitis (UC), or Crohn’s Disease (CD), or inflammatory
bowel disease (not otherwise specified) (IBD (nos)) recorded on the database since 1987;
patients with ICD-10 Read Codes (K50-K51) records of both UC and IBD were coded as UC;
CD plus IBD were coded as CD; individual records which included both UC and CD were
included only in analyses of IBD (nos). Prevalent IBD cases on 01.01.1987 were excluded. The
index date was defined as the date of first recording of IBD. Lifetime IBD severity was deter-
mined using an algorithm based on IBD drug-use (5-ASAs, corticosteroids, and immunosup-
pressants) and surgical intervention (colectomy/stomata) developed by team members with
clinical and research expertise in IBD.
Age, sex and practice matched controls were allocated the same index date as their matched
case. Because IHD has not been subjected to the same specific validation studies as IBD, our
operational definition was developed using advice from clinicians with special interest in car-
diovascular disease to include the following: Read Codes for IHD (to include myocarditis; myo-
cardial infarction; acute coronary syndrome; angina; confirmation by exercise treadmill or
referral to cardiologist; current prescriptions for glyceryl trinitrate; isosorbide mononitrate; iso-
sorbide dinitrate; nicorandil; ivabradine) Coronary Heart Disease (CHD) was considered for
the purpose of this study to be synonymous with IHD and Read Codes for coronary heart dis-
ease (including coronary artery disease) were included.
Ethics Statement
Data was accessed within limits set out by the Medical Research Council licence agreement for
academic access with Medical Research Ethics Committee ethical approval. The proposal was
approved by the Independent Scientific Advisory Committee of the GPRD (protocol number
10_003).
Analysis
Descriptive analysis of baseline characteristics and exploration of the direction of association
between IBD and IHD was conducted using the whole cohort of patients aged over 15 years
(COHORT A: n = 94,898). Subsequent analysis of the a priori hypothesis, that IHD followed
IBD, was conducted on a subset which included cases of IHD following IBD and their associ-
ated matched controls (COHORT B: n = 77540).
The relative risks of ischaemic heart disease (IHD) and its sub-entities myocardial infarction
(MI) and angina), as well as CHD were estimated as hazard ratios (HRs) for patients with IBD
compared to non-IBD patients, using Cox proportional hazard models. Models were subse-
quently adjusted for age, gender, socio-economic status (using general practice postcode as a
proxy), comorbidity and concomitant drug use, IBD disease severity, and smoking status. We
carried out both forward and backward stepwise covariate selection within the cox propor-
tional hazard model. All covariates were initially included with entry testing based on the sig-
nificance of the score statistic, and removal testing based on the probability of a likelihood-
ratio statistic based on conditional parameter estimates. Models were tested for interactions
between fitted variables. Precision of estimates is reported using 95% confidence intervals.
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Data management was performed using Stata 10IC. Cox regression proportional hazard com-
putations and Kaplan-Meier survival analysis were conducted using SPSS 21.
Results
Baseline cohort characteristics
Data were examined from electronic primary care records from 221 general practices across
the UK from patients with a first diagnosis of IBD recorded from 1st January 1987 to 31st
December 2009 (Fig 1). Following exclusions, data from COHORT A (patients with IBD and
matched controls aged over 15 years) was analysed to understand baseline characteristics and
exploration of the direction of association between IBD and IHD (COHORT A: n = 94898,
Tables 1 and 2). A subset of patients with IHD following IBD and their associated matched
controls (COHORT B: n = 77540) was analysed to examine baseline characteristics and the
strength of association between IBD and IHD (Tables 3–5). The mean follow up period was 6.8
years (SD 5.9). All-cause mortality during follow-up was 6353 (6.7%).
Temporal relationship between IBD and IHD (COHORT A)
Of 19163 IBD cases, a total of 2220 (11.6%) had an IHD diagnosis ever, compared with 6504
(8.6%) of those without IBD. Of these IHD diagnoses, 4494 (51.5%) occurred prior to IBD
diagnosis (1404 (63.2%) of IBD cases and 3090 (47.5%) of controls) (Fig 2). According to IBD
type, of 12,397 cases of Ulcerative Colitis, 1557 (12.6%) had an IHD diagnosis ever, and of
these, 980 (62.9%) occurred prior to IBD diagnosis; while of 4620 cases of Crohn’s Disease, 445
(9.6%) had an IHD diagnosis ever, of which 284 (63.8%) occurred prior to IBD diagnosis (S1–
S7 Figs). Similar temporal trends were seen in angina, MI and CHD. Sub-group analysis of
IHD cases diagnosed during or after the year 2004 also showed similar temporal trends. An
increased incidence of IHD, angina, MI, and CHD diagnoses was seen in the first year after
IBD diagnosis (S1–S6 Figs) but the mean age of IHD diagnosis comparing IBD cases with non
IBD cases was not statistically different apart from those with Ulcerative Colitis (UC) who
were slightly younger at diagnosis of angina and coronary heart disease (Table 2; S7 Fig). Of
those developing IHD following an IBD diagnosis, patients with UC were at higher risk of a
diagnosis of IHD (unadjusted HR 1.3, 95% CI 1.1–1.5, p<0.001) or MI (unadjusted HR 1.4,
95% CI 1.1–1.6, p = 0.004). Adjustment for a range of factors including age and gender showed
interaction between variables; models did not reach statistical significance and thus are not
reported here.
Subset characteristics (COHORT B: IBD preceding IHD)
A total of 17358 patients were excluded from subgroup analysis where IHD preceded IBD or,
for controls, the matched IBD date (associated cases/controls were also excluded in order to
protect matching of the resulting subset) (Fig 1). Subset characteristics (n = 77540) were com-
parable to those of the whole cohort (Table 3). Overall, the incidence of IHD following IBD
diagnosis (or matched control date) was similar to those without IBD (3.8% vs 3.9% p = 0.001).
The incidence of IHD following IBD diagnosis (or matched control) was slightly higher in
those with Ulcerative Colitis and lower in those with Crohn’s disease compared with patients
without IBD (4.4% vs 3.0% vs 3.8%, p = 0.042). This trend was also seen in angina, MI and
CHD (Table 4). In unadjusted analysis, Ulcerative Colitis was associated with a small but statis-
tically significant increased risk of IHD, and MI (HR 1.3, 95% CI 1.1–1.5, p<0.001; HR 1.4,
95% CI 1.1–1.6, p = 0.004 respectively) (Table 5). Use of 5ASAs did not alter this risk but users
of corticosteroids were at significantly greater risk of IHD and its subtypes.
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Fig 1. Cohort Flowchart. Selection of patients into two cohorts for analysis: COHORT A for descriptive analysis to examine the temporal relationship
between IBD and IHD, and COHORT B for sub-group analysis of IHD cases which occurred following IBD diagnosis.
doi:10.1371/journal.pone.0139745.g001
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Table 1. COHORT A characteristics comparing non-IBD controls with IBD cases (15 years).
Characteristics Non-IBD (n (%)) Crohn’s Disease (n (%)) Ulcerative Colitis(n (%)) IBD (NOS) (n (%)) P6
Total number 75735 (79.8%) 4620 (4.9%) 12397 (13.1%) 2146 (2.2%)
Male 36028 (47.6%) 1991 (43.0%) 5883 (47.5%) 913 (42.5%) <0.001
Age
15-34y 21759 (28.7%) 1816 (39.3%) 2960 (23.9%) 699 (32.6%)
35-49y 19365 (25.6%) 1115 (24.1%) 3182 (25.7%) 591 (27.5%)
50-64y 17089 (22.6%) 886 (19.2%) 3036 (24.5%) 421 (19.6%)
65+y 17522 (23.1%) 803 (17.4%) 3219 (26.0%) 435 (20.3%)
Mean age at entry (SD) 48.8 (SD 18.9) 44.2 (SD 18.9) 50.9 (SD 18.5) 46.9 (SD 19.0) <0.001
IBD severity1
Mild - 2325 (50.3%) 8141 (65.7%) 1424 (66.4%)
Moderate - 1572 (34.0%) 3220 (26.0%) 594 (27.7%)
Severe - 723 (15.7%) 1036 (8.4%) 128 (6.0%)
Smoker2
Never 27635 (54.4%) 540 (60.1%) 1429 (68.1%) 232 (66.7%)
Ever 23120 (45.6%) 358 (39.9%) 669 (31.9%) 116 (33.3%) <0.001
BMI3
<10 4 (0.0%) 1 (0.0%) 1 (0.0%) 0 (0.0%)
11–15 197 (0.3%) 29 (0.8%) 37 (0.4%) 6 (0.3%)
16–18.49 1415 (2.3%) 195 (5.2%) 259 (2.6%) 51 (2.9%)
18.5–24.9 25499 (40.8%) 1769 (47.0%) 4220 (41.8%) 769 (43.2%)
25–30 22523 (36.0%) 1130 (30.0%) 3557 (35.3%) 622 (34.9%)
>30 12878 (20.6%) 645 (17.1%) 2014 (20.0%) 333 (18.7%)
Mean (SD) 26.5 (SD 5.4) 25.4 (SD 5.5) 26.3(SD 5.3) 26.2 (SD 5.68) 0.198
Practice IMD4
0 4758 (20.6%) 271 (14.2%) 811 (16.1%) 108 (13.7%) <0.001
1 4797 (20.7%) 391 (20.5%) 1010 (20.1%) 160 (20.3%) <0.001
2 3451 (14.9%) 374 (19.6%) 967 (19.2%) 138 (17.5%) <0.001
3 6320 (27.3%) 443 (23.2%) 1193 (23.7%) 205 (26.1%) <0.001
4 3836 (16.6%) 431 (22.6%) 1050 (20.9%) 176 (22.4%) <0.001
Comorbidities
Rheumatoid Arthritis 1180 (1.6%) 101 (2.2%) 321 (2.6%) 43 (2.0%) <0.001
Diabetes type 2 4869 (6.4%) 214 (4.6%) 849 (6.9%) 108 (5.0%) 0.108
Diabetes type 1 599 (0.8%) 42 (0.9%) 153 (1.2%) 22 (1.0%) <0.001
Chronic kidney disease 3567 (4.7%) 156 (3.4%) 590 (4.8%) 91 (4.2%) 0.046
Contraceptive use 7954 (10.5%) 1004 (21.7%) 1757 (14.2%) 459 (21.4%) <0.001
IBD drug use5
5-Aminosalicylic acid 445 (0.6%) 3264 (70.7%) 9085 (73.3%) 1380 (64.3%) <0.001
Oral Corticosteroids 10178 (13.4%) 3140 (68.0%) 8046 (64.9%) 1243 (57.9%) <0.001
Azathioprine/methotrexate 650 (0.9%) 1456 (31.5%) 1983 (16.0%) 326 (15.2%) <0.001
Tumour necrosis factor α antagonists 58 (0.8%) 14 (0.3%) 111 (0.9%) 16 (0.8%) <0.001
Charlson Score5
0 43422 (70.2%) 2458 (62.6%) 5930 (59.7%) 1116 (62.1%)
1 10430 (16.9%) 908 (23.1%) 2204 (22.2%) 414 (23.0%)
2 4190 (6.8%) 277 (7.1%) 877 (8.8%) 132 (7.3%)
3 2109 (3.4%) 146 (3.7%) 468 (4.7%) 70 (3.9%)
4 834 (1.3%) 65 (1.7%) 210 (2.1%) 30 (1.7%)
5 438 (0.7%) 23 (0.6%) 89 (0.9%) 9 (0.5%)
(Continued)
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Table 1. (Continued)
Characteristics Non-IBD (n (%)) Crohn’s Disease (n (%)) Ulcerative Colitis(n (%)) IBD (NOS) (n (%)) P6
6 or more 459 (0.7%) 51 (1.3%) 154 (1.6%) 27 (1.5%) <0.001
Major abdominal surgery6 0 (0.0%) 635 (16.2%) 712 (7.2%) 102 (5.7%) <0.001
Stoma 0 (0.0%) 222 (5.7%) 460 (4.6%) 51 (2.8%) <0.001
1Estimated using IBD-drug use and surgical interventions during follow-up as proxies (see text for further detail)
2 43% of patients had missing data
3 17.4% of patients had missing data
4Index of Multiple Deprivation (IMD) based on practice post-code. Quintile 0 is the least deprived, quintile 4 is the most deprived. 67.5% of patients had
missing data.
5Ever in patient record
6 Non-IBD compared to IBD, comparison of binary variables by adjusted χ2 test; continuous variables by Student’s t-test; multiple category variables by χ2
test adjusted for trend.
doi:10.1371/journal.pone.0139745.t001
Table 2. Mean age at diagnosis of ischaemic heart disease comparing patients with and without IBD
(COHORT A)*.
Mean age at diagnosis of heart disease (SD, 95% CI1, p)
All heart disease2
CD cases 65.2 13.4 -3.8–1.6 0.435
CD controls 66.3 3.5 1-3.8–1.7
UC 65.8 11.7 -2.6–-0.2 0.021
UC controls 67.4 12.6 -2.8–0.3
Angina
CD cases 62.0 11.3 -7.8–0.0 0.052
CD controls 65.9 12.6 -7.5–-0.2
UC 64.5 11.0 -4.4–-0.7 0.008
UC controls 67.0 12.3 -4.4–-0.8
Coronary Heart Disease
CD cases 65.7 12.7 -4.7–2.7 0.589
CD controls 66.7 12.5 -4.8–2.8
UC 65.7 11.9 -3.9–-0.4 0.015
UC controls 67.9 11.7 -3.9–-0.4
Ischaemic Heart Disease
CD cases 68.0 13.6 -2.9–4.8 0.619
CD controls 67.0 12.9 -3.0–5.0
UC 67.3 11.2 -2.4–1.1 0.460
UC controls 68.0 12.5 -2.3–1.0
MI
CD cases 67.5 13.4 -4.8–5.6 0.877
CD controls 67.1 14.3 -4.7–5.5
UC 66.3 12.1 -4.2–0.9 0.193
UC controls 67.9 13.3 -4.2–0.7
1 95% Confidence Interval of the Difference between patients with and without IBD using Student’s T-Test
2incorporates IHD, CHD, angina and MI
*Analysis excludes cases of IHD diagnosed prior to IBD diagnosis.
doi:10.1371/journal.pone.0139745.t002
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Table 3. COHORT B characteristics comparing non-IBD controls with IBD cases*.
Characteristics Non-IBD (n(%)) Crohn’s Disease (n(%)) Ulcerative Colitis (n(%)) IBD (NOS) (n(%)) P7
Total number 61882 (79.8%) 3928 (5.1%) 9932 (12.8%) 1798 (2.3%)
Male 29895 (48.3%) 1686 (42.9%) 4667 (47.0%) 758 (42.2%) <0.001
Age
15-34y 21700 (35.1%) 1815 (46.2%) 2948 (29.7%) 697 (38.8%)
35-49y 18868 (30.4%) 1087 (46.2%) 3102 (29.7%) 574 (31.9%)
50-64y 13192 (21.3%) 667 (17.0%) 2354 (23.7%) 341 (19.0%)
65+y 8122 (13.1%) 359 (9.1%) 1528 (15.4%) 186 (10.3%)
Mean age at entry (SD) 46.6 (SD 20.6) 39.9 (SD 16.6) 46.2 (SD 16.8) 42.3 (SD 16.6) 0.495
IBD severity1
Mild - 1952 (49.7%) 6547 (65.9%) 1192 (66.3%)
Moderate - 1338 (34.1%) 2532 (25.5%) 502 (27.9%)
Severe - 638 (16.2%) 853 (8.6%) 104 (5.8%)
Smoker2
Never 27635 (54.4%) 540 (60.1%) 1429 (68.1%) 232 (66.7%)
Ever 23120 (45.6%) 358 (39.9%) 669 (31.9%) 116 (33.3%) <0.001
BMI3
<10 4 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
11–15 143 (0.3%) 27 (0.8%) 23 (0.3%) 3 (0.2%)
16–18.49 1151 (2.2%) 180 (5.4%) 198 (2.4%) 44 (2.9%)
18.5–24.9 21922 (41.3%) 1579 (47.7%) 3611 (43.0%) 668 (43.3%)
25–30 18909 (35.6%) 963 (29.1%) 2901 (34.5%) 538 (34.9%)
>30 10948 (20.6%) 558 (16.9%) 1671 (19.9%) 288 (18.7%)
Mean (SD) 26.5 (SD 5.4) 25.3 (SD 5.4) 26.3 (SD 5.3) 26.2 (SD 5.4) <0.001
Practice IMD4
0 3743 (21.0%) 242 (14.9%) 650 (16.3%) 86 (13.4%) <0.001
1 3722 (20.8%) 335 (20.6%) 792 (19.9%) 125 (19.4%) <0.001
2 2574 (14.4%) 310 (19.0%) 774 (19.4%) 112 (17.4%) <0.001
3 4827 (27.0%) 384 (23.6%) 948 (23.8%) 164 (25.5%) <0.001
4 2996 (16.8%) 358 (22.0%) 821 (20.6%) 157 (24.4%) <0.001
Comorbidities
Rheumatoid Arthritis 826 (1.3%) 75 (1.9%) 234 (2.4%) 29 (1.6%) <0.001
Diabetes type 2 3040 (4.9%) 136 (3.5%) 532 (5.4%) 70 (3.9%) 0.309
Diabetes type 1 421 (0.7%) 21 (0.5%) 95 (1.0%) 16 (0.9%) 0.032
Chronic kidney disease 2022 (3.3%) 103 (2.6%) 365 (3.7%) 55 (3.1%) 0.653
Contraceptive use 7894 (12.8%) 999 (25.4%) 1730 (17.4%) 456 (25.4%) <0.001
IBD drug use
5-Aminosalicylic acid 327 (0.5%) 2811 (71.6%) 7352 (74.0%) 1160 (64.5%) <0.001
Oral Corticosteroids 7455 (12.0%) 2665 (67.8%) 6415 (64.6%) 1038 (57.7%) <0.001
Azathioprine/methotrexate 474 (0.8%) 1320 (33.6%) 1709 (17.2%) 301 (16.7%) <0.001
Tumour necrosis factor α antagonists 43 (0.1%) 12 (0.3%) 98 (1.0%) 12 (0.7%) <0.001
Charlson Score5
0 43422 (70.2%) 2458 (62.6%) 5930 (59.7%) 1116 (62.1%)
1 10430 (16.9%) 908 (23.1%) 2204 (22.2%) 414 (23.0%)
2 4190 (6.8%) 277 (7.1%) 877 (8.8%) 132 (7.3%)
3 2109 (3.4%) 146 (3.7%) 468 (4.7%) 70 (3.9%)
4 834 (1.3%) 65 (1.7%) 210 (2.1%) 30 (1.7%)
5 438 (0.7%) 23 (0.6%) 89 (0.9%) 9 (0.5%)
(Continued)
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In order to examine the subset in a way that was consistent with previous research,[13] the
incidence rate ratios (IRR) for IHD were calculated (Table 6), comparing COHORT B, the par-
titioned subset, (i.e. IHD>IBD) with COHORT A (i.e. IHD event ever). The IRR for COHORT
A was 2.1 in the first year of IBD diagnosis, with an overall IRR of 1.8. In the partitioned subset
(COHORT B), the IRR in the first year of IBD diagnosis was lower (1.26) and similarly low
overall IRR (1.22).
Discussion
This is the first study to fully examine both the strength and direction of association between
development of ischaemic heart disease (IHD) and IBD. An increased incidence of IHD,
angina, MI, and CHD diagnoses was seen in the first year after IBD diagnosis but the mean age
of diagnosis comparing IBD cases with non IBD cases was not statistically different, apart from
those with Ulcerative Colitis (UC) who were slightly younger at diagnosis of angina and coro-
nary heart disease. Of those developing IHD following an IBD diagnosis, patients with UC
were at slightly higher risk of a diagnosis of IHD or MI although results were not significant
after adjustment for the role of covariates. Most notably, we found that although overall preva-
lence of IHD was higher in those with IBD, in the majority of cases the diagnosis of IHD actu-
ally predated that of IBD.
Table 3. (Continued)
Characteristics Non-IBD (n(%)) Crohn’s Disease (n(%)) Ulcerative Colitis (n(%)) IBD (NOS) (n(%)) P7
6 or more 459 (0.7%) 51 (1.3%) 154 (1.6%) 27 (1.5%) <0.001
Major abdominal surgery6 0 (0.0%) 635 (16.2%) 712 (7.2%) 102 (5.7%) <0.001
Stoma 0 (0.0%) 222 (5.7%) 460 (4.6%) 51 (2.8%) <0.001
1Estimated using IBD-drug use as proxies (see text for further detail)
230.2% of patients had missing data during follow-up (index date to IHD date or end of follow-up).
314.2% of patients had missing data during follow-up (BMI record nearest to IHD date (+-12 months)).
4Index of Multiple Deprivation (IMD) based on practice post-code. Quintile 0 is the least deprived, quintile 4 most deprived.
5Charlson index [17] is a validated index of comorbidity taking into account both the number and severity of comorbidities. 0 is no comorbidities. 6 or more
is a very high score indicating a high number of cormorbidities and/or severe comorbidities. For example AIDS and metastatic tumour each score 6.
6Colectomy during follow-up (index date to IHD date or end of follow-up).
7Non-IBD compared to IBD, comparison of binary variables by adjusted χ2 test; continuous variables by Student’s t-test; multiple category variables by χ2
test adjusted for trend
*Analysis excludes cases of IHD diagnosed prior to IBD diagnosis.
doi:10.1371/journal.pone.0139745.t003
Table 4. Incidence of IHD among cases and controls (COHORT B)*.
Non-IBD Crohn’s Disease Ulcerative Colitis IBD (NOS)
All heart disease1 2343 (3.8%) 117 (3.0%) 434 (4.4%) 56 (3.1%)
Angina 1172 (1.9%) 48 (1.2%) 196 (2.0%) 33 (1.8%)
CHD 1251 (2.0%) 55 (1.4%) 215 (2.2%) 26 (1.4%)
IHD 1162 (1.9%) 57 (1.5%) 238 (2.4%) 32 (1.8%)
MI 673 (1.1%) 36 (0.9%) 131 (1.3%) 20 (1.1%)
1incorporates IHD, CHD, angina and MI
*Analysis excludes cases of IHD diagnosed prior to IBD diagnosis.
doi:10.1371/journal.pone.0139745.t004
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This is the largest British cohort study to examine this issue. It used the General Practice
Research Database which is an appropriate and reliable resource for IBD research, having been
used for at least 19 studies published in peer-reviewed journals since 2000. The diagnostic reli-
ability of IBD diagnosis and the year of IBD diagnosis in the GPRD has been confirmed in a
recent validation study.[14] Other GPRD validation studies have confirmed reliable recording
Table 5. Unadjusted hazard ratios for cardiovascular disease comparing IBD drug users* and non-users (COHORT B).
HR (95%CI), p
unadjusted
comparing IBD
and non-IBD
patients
HR (95%CI), p
unadjusted comparing
users of Azathioprine/
methotrexate1 and non-
users
HR (95%CI), p
unadjusted comparing
users of Tumour
necrosis factor α
antagonists1 and non-
users
HR (95%CI), p
unadjusted
comparing users of
5ASAs1 and non-
users
HR (95%CI), p
unadjusted comparing
users of Corticosteroids1
and non-users
Cardiovascular
disease
IBD 1.2 (1.1–1.3),
p<0.001
1.0 (0.8–1.1) p = 0.614 1.5 (0.8–2.8) p = 0.256 1.2 (1.1–1.3) p =
<0.001
1.8 (1.6–1.9) p<0.001
CD 1.2 (1.0–1.5),
p = 0.059
0.8 (0.6–1.2) p = 0.327 1.4 (0.2–9.8) p = 746 1.1 (0.9–1.4)
p = 0.322
1.7 (1.4–2.0) p<0.001
UC 1.2 (1.1–1.4)
p<0.001
1.1 (0.9–1.4) p = 0.324 1.0 (0.4–2.4) p = 0.997 1.2 (1.1–1.4)
p = 0.001
1.8 (1.6–1.9) p<0.001
Angina
IBD 1.1 (1.0–1.2)
p = 0.235
1.0 (0.7–1.2) p = 0.653 2.0 (0.9–4.4) p = 0.095 1.1 (0.9–1.2)
p = 0.449
1.8 (1.6–2.0) p<0.001
CD 1.0 (0.8–1.4)
p = 0.836
0.7 (0.4–1.2) p = 0.141 0.1 (0.0–241) p = 0.702 1.1 (0.8–1.5)
p = 0.654
2.0 (1.6–2.6) p<0.001
UC 1.1 (0.9–1.2)
p = 0.428
1.2 (0.9–1.6) p = 0.287 1.2 (0.4–3.7) p = 0.753 1.0 (0.9–1.2)
p = 0.703
1.7 (1.5–2.0) p<0.001
Coronary Heart
Disease
IBD 1.1 (1.0–1.3)
p = 0.081
1.2 (0.9–1.4) p = 0.210 1.9 (0.8–4.2) p = 0.128 1.2 (1.0–1.4)
p = 0.022
1.7 (1.6–1.9) p<0.001
CD 1.1 (0.8–1.5)
p = 0.459
1.0 (0.7–1.6) p = 0.929 2.7 (0.4–19.1) p = 0.326 1.2 (0.9–1.7)
p = 0.250
1.9 (1.5–2.5) p<0.001
UC 1.1 (1.0–1.3)
p = 0.108
1.3 (1.0–1.7) p = 0.038 1.5 (0.6–4.1) p = 0.404 1.2 (1.0–1.4)
p = 0.093
1.7 (1.5–1.9) p<0.001
Ischaemic Heart
Disease
IBD 1.3 (1.2–1.5)
p<0.001
1.0 (0.7–1.2) p = 0.688 1.9 (0.9–4.3) p = 0.107 1.3 (1.2–1.5)
p<0.001
1.8 (1.6–2.0) p<0.001
CD 1.2 (1.0–1.6)
p = 0.180
0.8 (0.5–1.3) p = 0.375 3.0 (0.4–21.6) p = 0.268 1.3 (0.9–1.8)
p = 0.145
1.9 (1.5–2.4) p<0.001
UC 1.3 (1.1–1.5)
p<0.001
1.1 (0.9–1.5) p = 0.388 1.2 (0.4–3.6) p = 0.789 1.3 (1.1–1.5)
p = 0.001
1.8 (1.6–2.0) p<0.001
MI
IBD 1.3 (1.1–1.5)
p = 0.002
1.1 (0.8–1.5) p = 0.464 1.1 (0.3–4.5) p = 0.878 1.4 (1.2–1.7)
p<0.001
1.8 (1.5–2.0) p<0.001
CD 1.2 (0.8–1.7)
p = 0.369
0.6 (0.3–1.3) p = 0.215 0.05 (0.0–485) p = 0.749 1.1 (0.7–1.7)
p = 0.652
1.5 (1.1–2.0) p = 0.021
UC 1.4 (1.1–1.6)
p = 0.004
1.5 (1.0–2.1) p = 0.036 0.7 (0.1–5.1) p = 0.737 1.5 1.2–1.8) p<0.001 1.9 (1.6–2.3) p<0.001
1Drug users with and without IBD were included in this analysis
*Analysis excludes cases of IHD diagnosed prior to IBD diagnosis.
doi:10.1371/journal.pone.0139745.t005
Ischaemic Heart Disease and Inflammatory Bowel Disease
PLOS ONE | DOI:10.1371/journal.pone.0139745 October 13, 2015 10 / 15
of cardiovascular disease and other disease groups.[15, 16] The risk of selection bias in this
study was low given that GPRD data is collected from a wide cross-section of general practices
from across the UK. The prevalence of CD is slightly lower compared to UC than would be
expected in a UK population [17]. However, the cohort was a random selection taken from 2
million records and the difference is unlikely to reflect systematic sampling bias. We were care-
ful to exclude from our analysis patients with chronic kidney disease and diabetes mellitus, since
both are associated with raised inflammatory markers and could have confounded our results.
As others have highlighted [13], there is a risk of ascertainment bias because IBD patients
may have more frequent contact with health care professionals and are therefore monitored
more closely, potentially raising the chance of earlier detection of IHD in this group. The fact
that patients with UC were at slightly higher risk of IHD and MI could potentially be a selec-
tion effect on a conditioned group or simply an artefact of multiple hypotheses in this hypothe-
sis generating study. We sought to overcome this by designing the study to examine the
direction of association and clearly delineating prevalent and incident IHD cases. In addition,
we allowed adjustment for the effect of comorbidities in both cases and controls by using the
Charlson index [18] as a composite measure of comorbidity within multiple analyses, all of
which demonstrated no difference between groups.
Fig 2. Time from IBD diagnosis (T0) to first IHD event according to IBD type. Total number of patients
showing time from IBD diagnosis (T0) to the first cardiovascular event (incorporating IHD, CHD, angina and
MI).
doi:10.1371/journal.pone.0139745.g002
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The temporal relationship between IBD and IHD may be weakened by differences with
which the diagnosis of each is recorded in the GPRD. IHD is a diagnosis made in the majority
of cases fairly soon after the onset of symptoms, because of an event requiring admission to
hospital (MI, acute coronary syndrome). Nevertheless, among those with stable angina, nearly
half have symptoms for 6 months or more before diagnosis.[19] For IBD the time to reach a
diagnosis may be longer. A Swiss cohort study of 1591 patients with IBD estimated the median
interval from first presentation to a GP to diagnosis as 4 months (IQR 0–18) for CD and 1
month (0–5) for UC.[20] Independent risk factors for delayed diagnosis included younger age
(<40) in Crohn’s disease and male sex in ulcerative colitis.[20]
It is possible that IHD cases may have been missed or incorrectly coded within GPRD.
Unrecorded diagnoses are increasingly unlikely within UK general practice due to policy and
fiscal incentives to assess, monitor and treat cardiovascular disease,[21] although historical rec-
ords pre-dating these incentives are more likely to have unrecorded IHD diagnoses. Sub-group
analysis comparing diagnoses of IHD and its subtypes before and after these incentives (around
the year 2004) demonstrate no differences either in temporal trends or in overall risk profiles,
thus decreasing the likelihood of reporting bias. Incorrect sub-group coding of types of IHD is
another possibility, partly as a result of lack of clinical consensus about definitional boundaries.
For this reason, we conducted sub-group analysis on MI, angina and additional group analysis
of cases coded as CHD and the fact that trends were entirely consistent with results for IHD
goes some way to refuting the potential for this type of recording bias. Although GPRD pre-
scribing and clinical data are robust and reliable, BMI and smoking data were incomplete due
to the fact that, in the UK, many general practices do not routinely or systematically collect this
data. Data on cholesterol levels were not requested. Thus the effect of these covariates on the
association between IHD and IBD remains unknown. We were unable to reliably differentiate
between remission and relapse phases, or to capture concomitant extraintestinal manifesta-
tions. These data would be recorded in secondary care but not routinely communicated to pri-
mary care in a way that would result in the event being routinely coded in the primary care
record, and hence the GPRD dataset. The potential association between relapses and incidence
of heart disease warrants further investigation.
This is the first known study to examine the temporal relationship between IHD and IBD
and we found that the majority of IHD cases predated IBD diagnosis. Previous research has
predominantly focused attention on incident cases of IHD occurring at or after diagnosis of
IBD. It is notable that the overall risk of prevalent (i.e. whole cohort) IHD was almost identical
to a recent Danish study [13] at 2.1 IRR, but that when this was limited to truly incident cases
post IBD, the risk reduced to 1.2 IRR. IBD is triggered by a complex interaction between envi-
ronmental factors, genetic predisposition, and an exaggerated immune response. Our findings
suggest that the temporal relationship between IBD and IHD is against the concept of the latter
being a long term consequence of IBD-related inflammation, as previously proposed [13].
Instead, the association with IHD is more plausibly explained by common mechanisms in the
inflammatory pathway, or even a reverse causality. Our findings suggest that the assessment of
Table 6. Incidence Rate Ratios (IRR) comparing whole group analysis with sub-set*.
Whole dataset (COHORT A) Sub-set (COHORT B)
Overall IRR (95% CI) IRR in 1st year > IBD diagnosis(95% CI) Overall IRR (95% CI) IRR in 1st year > IBD diagnosis (95% CI)
All IHD 1.8 (1.72–1.89) 2.1 (1.98–2.22) 1.2 (1.12–1.33) 1.3 (1.07–1.48)
*Analysis excludes cases of IHD diagnosed prior to IBD diagnosis.
doi:10.1371/journal.pone.0139745.t006
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a patient’s future risk of IHD should not be modified by the presence of IBD. Among patients
who develop IHD, those who have raised cytokine levels, particularly of IL6 and TNF Alpha,
may be at increased risk of subsequently developing IBD.
Conclusions
By identifying and quantifying both the strength and direction of association between IBD and
IHD, this study provides important insights into the burden of IHD in the IBD population.
This is relevant for basic scientists exploring the temporal causal pathway, and clinicians who
should be aware of the risks of IHD in patients with IBD and vice versa.
Supporting Information
S1 Fig. Time from IBD diagnosis (T0) to first CVD event by age. Total number of patients
showing time from IBD diagnosis (T0) to the first cardiovascular event (incorporating IHD,
CHD, angina and MI) according to IBD type and age categories.
(TIF)
S2 Fig. Time from IBD diagnosis (T0) to first CVD event by IBD type and gender. Total
number of patients showing time from IBD diagnosis (T0) to the first cardiovascular event
(incorporating IHD, CHD, angina and MI) according to IBD type and gender categories.
(TIF)
S3 Fig. Time from IBD diagnosis (T0) to first coronary heart disease event by IBD type.
Total number of patients showing time from IBD diagnosis (T0) to the first Coronary Heart
Disease (sub-group of CVD) event according to IBD type.
(TIF)
S4 Fig. Time from IBD diagnosis (T0) to first Ischaemic Heart Disease event by IBD type.
Total number of patients showing time from IBD diagnosis (T0) to the first Ischaemic Heart
Disease (sub-group of CVD) event according to IBD type.
(TIF)
S5 Fig. Time from IBD diagnosis (T0) to first angina event according to IBD type. Total
number of patients showing time from IBD diagnosis (T0) to the first Angina (sub-group of
CVD) event according to IBD type.
(TIF)
S6 Fig. Time from IBD diagnosis (T0) to first Myocardial Infarction event according to
IBD type Total number of patients showing time from IBD diagnosis (T0) to the first Myocar-
dial Infarction (sub-group of CVD) event according to IBD type.
(TIF)
S7 Fig. Age at CVD onset according to IBD type Total number of patients showing age at
onset of Cardiovascular Disease (incorporating IHD, CHD, angina and MI) according to IBD
type.
(TIF)
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